Defining Benign/Burnt-Out MS and Discontinuing Disease-Modifying Therapies.

Objective: To determine whether MS disease-modifying therapies (DMTs) can be safely discontinued in patients aged 50 years or older with suspected benign/burnt-out MS and to define criteria to identify such patients.

Methods: We conducted a retrospective cohort study of 136 patients with suspected benign/burnt-out MS who discontinued DMTs from the electronic health record (EHR) at Kaiser Permanente Southern California.

Results: The majority discontinued an injectable DMT (n = 131, 96%).